Research Article
Improvement of Quality of Life after Surgical Treatment of Patients with MRONJ: A Prospective Analysis Using the SF-12 and OHIP-14 Questionnaires
Table 3
Distribution of drugs and route of administration (n = 27).
| | Medication | Dose | No. of pat. (%) |
| | Alendronate (oral) | 70 mg once weekly | 1 (3.7%) | | Pamidronate (i.v.) | 90 mg once monthly | 1 (3.7%) | | Zoledronate (i.v.) | 4 mg once monthly | 16 (59.3%) | | Denosumab (s.c.) | 60 mg every 6 months (7 patients) 120 mg once monthly (2 patients) | 9 (33.3%) | | Route of administration | — | — | | Oral | — | 1 (3.7%) | | Subcutaneous | — | 9 (33.3%) | | Intravenous | — | 17 (63.0%) |
|
|
